In a phase 1 clinical trial, a novel mesenchymal stem cell [MSCs] therapy was successfully applied to treat often fatal steroid resistant graft versus host disease [GVHD]. A significant concern with life-saving organ and bone marrow transplants is the risk of immune rejection. GVHD occurs when the transplanted immune cells attack the patient’s body, with patients typically suffering from painful ulcers all over the body, and in extreme cases, death. The therapy, created by Cynata Therapeutics, is called CYP-001, and utilizes mesenchymal stem cells [the same type of cells found in teeth] to treat steroid resistant GVHD. This treatment gives hope to thousands of patients around the world receiving bone marrow transplants and risking the extremely fatal immune response.
In the first phase of the clinical study, the patient survival rate was 87.5%, which amounts to 7 out of 8 patients surviving this notoriously fatal complication. Dr. Kilian Kelly, Vice President of product development at Cynata comments, “Steroid-resistant GVHD is a horrific disease, which causes debilitating symptoms and a very high rate of mortality, so we are delighted to see such positive outcomes among participants of cohort A of this ground-breaking trial.” Cynata will continue with Phase II and patients are currently being recruited to further examine the efficiency and best dosage of this treatment.
Advances in stem cell based regenerative treatments are creating more effective treatment options for patients suffering from a wide variety of disease, trauma and injury. To learn more about stem cells, and how families can bank their own valuable stem cells by recovering the very powerful dental pulp stem cells during routine dental procedures; such as wisdom teeth extractions or the during the loss of baby teeth, visit StemSave or call 877-783-6728 (877-StemSave) today.
The Future of Regenerative Medicine is Now™
To view the full article, click here.